Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atif Baqai

Vascular Surgery Park Ridge, IL Medical Doctor

NPI 1508066192 CMS profile 68186

1875 Dempster St Ste 550, Park Ridge, IL 60068

Open in the dashboard

General payments

$567,438

774 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$45,269 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Atif Baqai of Park Ridge, IL is reported in the CMS Open Payments database as having received $567,438 across 774 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $45,269 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $172,285 166
2024 General $115,301 141
2023 General $82,274 131
2022 General $97,665 123
2021 General $46,742 67
2020 General $36,671 58
2019 General $16,500 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atif Baqai
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Atif Baqai were reported at $172,285. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Atif Baqai Vascular Surgery median Middle half National median
2019 $16,500 $796 $226–$2,363 $163
2020 $36,671 $348 $118–$1,110 $114
2021 $46,742 $471 $158–$1,421 $132
2022 $97,665 $725 $222–$2,183 $149
2023 $82,274 $836 $257–$2,440 $160
2024 $115,301 $909 $252–$2,619 $164
2025 $172,285 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $134,591 80 payments
  2. Inari Medical, Inc. $106,960 140 payments
  3. Janssen Pharmaceuticals, Inc $78,228 86 payments
  4. Shockwave Medical, Inc $72,979 60 payments
  5. Silk Road Medical, Inc. $57,679 79 payments
  6. LeMaitre Vascular, Inc. $31,216 33 payments
  7. MIMEDX Group, Inc. $30,563 25 payments
  8. Stryker Corporation $24,089 31 payments
  9. Medtronic, Inc. $8,886 34 payments
  10. W. L. Gore & Associates, Inc. $7,280 59 payments
  11. Other $14,969 147 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $171,150 77 payments
  2. Consulting Fee $156,524 79 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $81,025 26 payments
  4. Travel and Lodging $64,948 178 payments
  5. Honoraria $57,200 9 payments
  6. Food and Beverage $27,649 398 payments
  7. Education $8,943 7 payments
Products named General payments · program years 2019–2025
  1. CT THROMBECTOMY SYSTEM KIT $127,131 153 payments
  2. FLOWTRIEVER CATHETER, S $127,131 153 payments
  3. Kerecis SurgiClose Wound Care $98,897 52 payments
  4. Kerecis GraftGuide $98,897 52 payments
  5. Kerecis SurgiClose Wound Care $98,897 52 payments
  6. Kerecis SurgiClose Wound Care $98,897 52 payments
  7. Kerecis SurgiClose Wound Care $98,897 52 payments
  8. XARELTO $78,228 86 payments
  9. Kerecis Omega3 SurgiClose $35,693 28 payments
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $32,994 37 payments
  11. Other $459,666 742 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

376

Median for Vascular Surgery: 122

Drug cost

$133,308

Median for Vascular Surgery: $14,135

Branded share of claims

73.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 121 $84,191
Eliquis Apixaban Brand 39 $36,363
Brilinta Ticagrelor Brand 12 $9,598
Cilostazol Generic 61 $1,377
Clopidogrel Clopidogrel Bisulfate Brand 105 $1,343
Atorvastatin Calcium Generic 38 $436

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$207,726

Medicare's payments for the services billed

Medicare patients

593

Average age 76

Services billed

2,180

308 women, 285 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 53%
Diabetes 41%
Chronic kidney disease 39%
Heart failure 35%
Atrial fibrillation 34%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $16,349
$16,349 121 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

774 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record